Academician Zhou confirmed for the first time that there are racial differences in drug metabolism and drug response worldwide, and found a new mutant gene (CYP2C 19 * 5). The theory that CYP2C 19 has gene dose effect in the population was put forward and proved for the first time. In recent years, the research on the role of pharmacogenomics in drug therapy and disease occurrence is at the forefront of the world, which provides theoretical support and experimental basis for the future gene-oriented drug therapy model in China.

Cardiovascular pharmacology has always been a traditional dominant discipline in our school, and the older generation has professors Chen Xiu and Guo Zhaogui. In recent years, Professor Li discovered for the first time that calcitonin gene-related peptide (abbreviated as CGRP) is closely related to the occurrence and development of hypertension. It is proved that endogenous ADMA is the main factor to promote atherosclerosis, and the proposed DDAH/ADMA metabolic enzyme system is the target to find anti-atherosclerosis drugs, and it is found that the anti-atherosclerosis and vascular endothelial protection of some traditional Chinese medicine components are related to this target. It explores a new way for drug treatment of cardiovascular and cerebrovascular diseases.

The innovative drug research and development team led by Professor Tan Guishan seeks and synthesizes new compounds by treating new targets. It was found that ketone, a natural product, can regulate the activity of DDAH/ADMA metabolic enzymes, and has the functions of protecting vascular endothelium and preventing atherosclerosis. A series of Akt/mTOR inhibitors VBE (national invention patents and PCT patents have been applied for) have been discovered from traditional Chinese medicine for the first time. A new class I anti-renal fibrosis drug, florfenidone, has completed pre-clinical research and is applying for clinical research (global patent has been applied).

The research direction of pharmacokinetics and clinical pharmacy led by Professor Li Huande is at the leading level in China in the fields of rational drug use, individualized drug administration, drug poisoning rescue and body fluid analysis. The new drug phase I clinical trial platform has carried out 150 pharmacokinetic and bioequivalence tests for pharmaceutical enterprises, and carried out 16 phase I clinical trials.